Medical Dispatch

Can Ozempic Cure Addiction?

奥赛奇能治愈成瘾吗?
GLP-1 drugs, which have helped some people curb drug and alcohol use, may unlock a pathway to moderation.
GLP-1类药物在帮助部分人群控制药物与酒精使用方面展现出潜力,或许能为适度节制开启一条新路径。
Still life with martini ozempic pen beakers and lab equipment
Illustration by Bianca Bagnarelli

Mary started drinking regularly in the early nineties, when she was thirteen. Her father had recently married a Danish woman and moved the family to Denmark, which has one of the highest teen-drinking rates in Europe. (Sixteen-year-olds are allowed to buy beer.) As Mary got older, her alcohol consumption accelerated—she could drink eighteen beers in a sitting—and a cycle of inebriation and hangovers blurred her days. She tried rehab, Alcoholics Anonymous, and a medication called Antabuse, which provokes nausea in combination with alcohol. None of them worked for her. Mary (a pseudonym) got married, had a child, and became a social worker; her alcohol tolerance increased so much that, when she binged, her friends barely registered that she was buzzed. She remembered a close friend who also drank heavily telling her, “I don’t get it. Why do you say you have an alcohol addiction?”

玛丽在九十年代初开始经常喝酒,那时她才十三岁。她的父亲刚娶了一位丹麦女子,举家迁往丹麦——那是欧洲青少年饮酒率最高的国家之一(十六岁即可合法购买啤酒)。随着年岁增长,玛丽的饮酒量不断攀升——她曾一次喝下十八罐啤酒——醉意与宿醉的循环让她的日子变得模糊不清。她尝试过康复治疗、匿名戒酒会,还服用过一种名为安塔布司的药物(这种药与酒精结合会引发恶心)。这些对她都无济于事。玛丽(化名)结了婚,生了孩子,成为一名社会工作者;她的酒精耐受度变得极高,纵使狂饮,朋友们也几乎察觉不到她微醺的状态。她记得一位同样酗酒的好友曾对她说:“我不明白。你为什么总说自己有酒瘾?”

“The difference between you and me,” Mary replied, “is that I think about alcohol all the time—when to drink, how to drink, where to drink, how much to drink.”

“你我的区别在于,”玛丽答道,“我无时无刻不在想着酒——何时喝,怎么喝,在哪儿喝,喝多少。”

Last year, at a bar, Mary noticed that the same friend had hardly sipped her drink. She told Mary that she’d started taking Ozempic for weight loss. “If I have more than two beers now, I go outside and barf,” the friend said. Mary was perplexed. Ozempic, or semaglutide, originated as a diabetes medicine; more recently, as an obesity treatment, it has made its manufacturer, Novo Nordisk, one of Europe’s most valuable companies. What did it have to do with drinking? The next day, Mary saw an advertisement on Facebook: a nearby clinical trial was studying semaglutide’s effects on alcohol addiction. She enrolled.

去年,在一家酒吧里,玛丽注意到那位朋友几乎没怎么喝自己杯里的酒。朋友告诉玛丽,她为了减肥开始服用Ozempic。“现在只要喝超过两杯啤酒,我就会跑到外面吐,”朋友说。玛丽感到困惑。Ozempic,即司美格鲁肽,最初是一种糖尿病药物;近来作为肥胖症疗法,它使其制造商诺和诺德成为欧洲市值最高的公司之一。这跟喝酒有什么关系?第二天,玛丽在Facebook上看到一则广告:附近的一项临床试验正在研究司美格鲁肽对酒精成瘾的影响。她报了名。

Once a week, researchers blindfolded Mary and injected her with a solution. They didn’t tell her whether she’d received semaglutide or a placebo. But, a few weeks into the study, she lost her taste for beer. She switched to white wine, then stopped drinking altogether. “People talk about Ozempic getting rid of food noise,” she told me. “For me, it took out alcohol noise.”

每周一次,研究人员会蒙上玛丽的眼睛,为她注射一剂溶液。他们不会告诉她注射的是司美格鲁肽还是安慰剂。但研究开始几周后,她突然对啤酒失去了兴趣。她改喝白葡萄酒,后来索性滴酒不沾。“人们总说'诺和泰'能消除对食物的念想,”她告诉我,“对我来说,它消除的是对酒精的念想。”

One way to think about addiction is as a battle between first- and second-order desires. On some level, you want a drink; on another, you don’t want to want a drink. Strikingly, Mary felt that semaglutide had not only curbed her first-order desire to drink but also helped her act on second-order desires. “Because alcohol was no longer an issue, all of this energy was released,” she said. “I finally had the mental space to think, What type of life do I want?” She’d had marital problems for years; within months of starting the trial, she left her wife. “I’d never dared make that decision,” she told me.

理解成瘾的一种方式,是将其视为一阶欲望与二阶欲望之间的斗争。在某个层面上,你想喝一杯;在另一个层面上,你不想让自己产生喝酒的欲望。引人注目的是,玛丽认为司美格鲁肽不仅抑制了她喝酒的一阶欲望,还帮助她践行了二阶欲望。“因为酒精不再是问题,所有能量都被释放出来了,”她说,“我终于有了心理空间去思考:我想要什么样的生活?”她的婚姻问题已持续多年;在开始试验的几个月内,她便离开了妻子。“我以前从不敢做这个决定,”她告诉我。

As the researchers increased the dose of the medication, however, Mary’s appetite vanished. Some days, she ate as few as two hundred calories. She had been overweight when the study began; she lost fifty-five pounds in five months. One afternoon, she cried in a grocery store because she was surrounded by food and didn’t want to eat. “I knew what I had to do, but there was no hunger,” she said. “I felt desperate.” Mary was supposed to take the drug for six months, but, after the weight loss continued even on a lower dose, she had to stop the drug two weeks early. Still, she maintained her lower weight with a strict diet-and-exercise regimen. Her cravings for alcohol returned, but she felt better able to control them. “These drugs can give you the break you need to jump-start changes in your life,” she told me. “People know how much they affect your body. I don’t think they realize how much they affect your mind.”

然而,随着研究人员增加药物剂量,玛丽的食欲消失了。有些日子,她摄入的热量不足两百卡路里。研究开始时她体重超标;五个月内她减掉了五十五磅。一天下午,她在杂货店里哭了,因为周围全是食物,她却毫无食欲。“我知道自己该吃东西,但就是感觉不到饥饿,”她说,“这太令人绝望了。”按计划玛丽应服药六个月,但即使在降低剂量后体重仍在持续下降,她不得不提前两周停药。尽管如此,她通过严格的饮食控制和锻炼计划维持了减重后的体型。对酒精的渴望虽已复现,但她感觉更能掌控这种冲动。“这类药物能给你一个喘息的机会,让你重新启动生活的改变,”她告诉我,“人们都知道它们对身体的影响有多大。但我觉得,人们还没意识到它们对心智的影响同样深远。”

When I asked addiction researchers about the promise of medications like Ozempic, they sounded as enthusiastic as Mary. GLP-1 medications—colloquially known as GLP-1s—mimic a naturally occurring hormone called glucagon-like peptide 1, which scientists have historically associated with digestion. In the traditional telling, after a meal, GLP-1 attaches to receptors in the pancreas, the gastrointestinal tract, and the brain; it stimulates the release of insulin, slows the passage of food through the stomach, and signals to our brains that we’re full. It breaks down within minutes. But it’s increasingly clear that GLP-1 affects much more than eating. GLP-1 drugs, which bind to the body’s receptors for hours or days, are now being studied for all sorts of addictions.

当我向成瘾研究者们询问像“诺和泰”(Ozempic)这类药物的前景时,他们的热情程度不亚于玛丽。GLP-1类药物——俗称“GLP-1激动剂”——模拟一种名为胰高血糖素样肽-1的天然激素,科学家们历来认为这种激素与消化功能相关。传统理论认为,进食后GLP-1会附着在胰腺、胃肠道和大脑中的受体上;它能刺激胰岛素释放,减缓食物通过胃部的速度,并向大脑传递饱腹信号。这种激素在数分钟内就会分解。但越来越明显的是,GLP-1的影响远不止于进食。如今科学家们正在研究这类能与人体受体结合数小时甚至数日的GLP-1药物,探索其对各种成瘾行为的潜在疗效。

The results from the trial that Mary participated in should come out later this year, but a small study published in 2021 showed that smokers given exenatide, the first GLP-1 on the market, were nearly twice as likely to stop smoking as those given a placebo. An analysis of hundreds of thousands of electronic health records found that people with an addiction to opioids who happened to be prescribed GLP-1s were forty per cent less likely to overdose. Some scientists think that the medications may even help with behavioral addictions, such as gambling and compulsive shopping. Research into GLP-1s, scientists hope, could deepen our understanding of what addiction is. “Essentially all addiction medications to date have been specific to a particular type of addiction,” Heath D. Schmidt, a neuroscientist at the University of Pennsylvania, told me. “GLP-1s might be telling us that there’s some kind of universal pathology when it comes to addiction. And that they’re part of how we fix it.”

玛丽参与的临床试验结果预计今年晚些时候公布,但2021年发表的一项小型研究显示,服用艾塞那肽(全球首款上市的GLP-1药物)的吸烟者成功戒烟的概率,几乎是服用安慰剂组的两倍。另一项针对数十万份电子健康记录的分析发现,恰巧服用GLP-1药物的阿片类药物成瘾者,用药过量的风险降低了四成。部分科学家认为这类药物甚至可能对赌博、强迫性购物等行为成瘾产生疗效。科研人员期待,对GLP-1药物的深入研究或将深化人类对成瘾本质的认知。“迄今为止,几乎所有成瘾治疗药物都只针对特定类型的成瘾,”宾夕法尼亚大学神经科学家希思·D·施密特(Heath D. Schmidt)告诉我,“GLP-1药物或许在向我们揭示:所有成瘾现象背后可能存在某种共通的病理机制。而这类药物,正是破解难题的关键组成部分。”

America’s first randomized trial of semaglutide for heavy alcohol use began in 2023 at the medical campus of the University of Colorado Anschutz, not far from Denver. On a frigid morning in December, I met its principal investigator, Joseph Schacht, in a sleek glass building within view of the snow-capped Rocky Mountains. Schacht, a lean clinical psychologist with boyish features, has spent much of his career searching for medications to treat alcohol addiction. Since the turn of the twenty-first century, drinking-related deaths have roughly doubled in the U.S., yet no new medication has been approved for alcohol addiction in decades. Schacht’s field has faced a basic challenge: risky drug use is usually hidden and stigmatized, which makes it difficult to study and treat. “I fundamentally believe that a medication you can take in the privacy of your home—that doesn’t require disclosing to others that you have this problem—is essential to be able to offer,” he told me.

2023年,美国首个针对重度饮酒者的司美格鲁肽随机试验在科罗拉多大学安舒茨医学院校区启动,这里距离丹佛不远。十二月一个寒冷的早晨,我在一栋能望见落基山脉雪峰的玻璃幕墙建筑里见到了试验的首席研究员约瑟夫·沙赫特。这位身形清瘦、面容带着少年气的临床心理学家,职业生涯大半都在寻找治疗酒精成瘾的药物。自二十一世纪以来,美国与饮酒相关的死亡人数已翻了一番,但几十年来却没有新药获批用于治疗酒精成瘾。沙赫特的研究领域始终面临一个根本性挑战:高危药物使用行为通常隐蔽且被污名化,这使得研究与治疗都举步维艰。“我坚信,一种能在家私密服用、无需向他人袒露自身问题的药物,是我们必须提供的治疗方案。”他这样告诉我。

Schacht escorted me to a storage room unlike any I’ve visited at a research laboratory. Stacked on a countertop were cocktail mixers: cranberry juice, pineapple juice, Fever-Tree pink-grapefruit soda. Inside a wooden cupboard were shelves of alcohol: Chardonnay, Zinfandel, Tito’s vodka, Jose Cuervo tequila, Mount Gay rum. Where another lab might have pipettes, this one had shot glasses. Schacht had agreed to put me through a cue-reactivity test—which exposes participants to a drug to see how strongly they want it—and to image parts of my brain involved in cravings for alcohol. Before the test, his staff will ask participants what they like to drink. (When participants have specified an ultra-top-shelf liquor, Schacht has been known to ask, “O.K., how often do you actually drink that?”)

沙赫特(Schacht)带我走进一间储藏室,那是我在科研实验室里从未见过的景象。操作台上堆满了调酒用的原料:蔓越莓汁、菠萝汁、菲味树(Fever-Tree)粉红西柚汽水。木柜里则陈列着一排排酒品:霞多丽、仙粉黛、提托(Tito's)伏特加、豪帅金快活(Jose Cuervo)龙舌兰、玛琅(Mount Gay)朗姆酒。别的实验室或许摆满移液器,这里却放着烈酒杯。沙赫特同意让我接受一项线索反应测试——让参与者接触成瘾物质,以观察其渴求强度——并扫描我大脑中与酒精渴求相关的区域。测试开始前,他的团队会询问参与者喜欢喝什么。(当有人点名要顶级奢华酒款时,沙赫特总会反问:“好吧,那你究竟多久喝一次那种酒?”)

My drink of choice is a Negroni. Across the hall from the storage room, I sat down at a table with an iPad on it. Melina Kilen, a disarmingly confident research assistant in a blue sweater and long earrings, arrived with a tray of bartending supplies. She unscrewed the cap from a bottle of gin, poured a shot into a glass over ice, and added sweet vermouth and Campari. I watched the liquid change from clear to golden to amber. Finally, she ran an orange peel around the rim, dropped it into the drink, and left the room.

我偏爱的鸡尾酒是尼格罗尼。在储藏室对面的大厅里,我坐在一张放着iPad的桌旁。梅丽娜·基伦(Melina Kilen)端着调酒托盘走了进来,这位研究助理穿着蓝色毛衣,戴着长耳环,举手投足间带着令人卸下心防的自信。她拧开琴酒瓶盖,往盛着冰块的玻璃杯里倒了一小杯,又加入甜味美思和金巴利。我看着杯中液体从透明转为金黄,再化作琥珀色。最后,她用橙皮抹了抹杯沿,将橙皮投入酒中,便离开了房间。
Man alone trying to sell snake oil while man next to him is successfully selling truffle snake oil.
Cartoon by Patrick McKelvie
Copy link to cartoon
Shop

A man’s voice emanated from a nearby laptop: “When you hear a high tone”—ding!—“pick up the glass, bring it to your nose, and smell the beverage. When you hear a low tone”—dong!—“stop smelling the beverage and move the glass away from your nose. Do not drink!” For five minutes, I followed instructions, inhaling the drink’s bitter and bright aromas and then putting the glass down again. I was hungry and tired, having flown in late the previous night, and I was surprised that even in a laboratory I wanted to take a sip. Then the test was over; the untouched Negroni was rather cruelly taken away.

旁边一台笔记本电脑里传来一个男人的声音:“听到高音时”——叮!——“拿起杯子,凑到鼻子前,闻饮料的气味。听到低音时”——咚!——“停止闻饮料,把杯子从鼻子前移开。不要喝!”接下来的五分钟里,我遵照指示,时而吸入饮料苦涩而清冽的香气,时而又把杯子放下。我既饿又累——前一天深夜才飞抵此地——连在实验室里都忍不住想啜饮一口,这让我自己都有些惊讶。随后测试结束;那杯未曾触碰的内格罗尼酒被相当残忍地收走了。

On the iPad, I answered some questions. The drink was alluring, I wrote, but not in an all-consuming way. In contrast, one of Schacht’s trial participants, a former I.C.U. nurse whom I’ll call Susan, told me that her cue-reactivity test was “torture.” She remembered sniffing a glass of wine for what seemed like forever. “I wanted that drink so bad,” she said. Before the trial, she’d often have a bottle of wine and a margarita or two per night.

在iPad上,我回答了几个问题。我写道,那杯酒确实诱人,但还不至于让人魂牵梦萦。相比之下,沙赫特(Schacht)的一位试验参与者——一位曾任职重症监护室的护士,我姑且称她为苏珊(Susan)——告诉我,她的线索反应测试简直是“酷刑”。她记得自己对着那杯葡萄酒闻了又闻,仿佛永无止境。“我太想喝那杯酒了,”她说。参加试验前,她每晚常会喝掉一瓶葡萄酒,外加一两杯玛格丽特。

Addiction is more than a subjective sensation; its patterns can be observed in the brain. Schacht told me that when specific brain regions respond more to alcohol than to, say, food, that’s “very predictive of alcohol-use disorder.” He led me to a nearby building that housed MRI scanners. After changing into scrubs, I lay on a padded table that glided into a cylindrical machine. I was holding a remote control that allowed me to rate the strength of my urge to consume alcohol. “Thumb for extreme,” a technician told me. “Pinkie for none.”

成瘾不止是一种主观感受;其模式可以在大脑中观察到。沙赫特告诉我,当特定脑区对酒精的反应比对食物等更强烈时,这“对酒精使用障碍具有极强的预测性”。他带我来到附近一栋设有磁共振成像扫描仪的建筑。换上手术服后,我躺在一张铺有软垫的平台上,滑入圆柱形机器。我手持一个遥控器,用来评估自己对酒精的渴望强度。“拇指代表极度渴望,”技术员告诉我,“小指代表毫无渴望。”

For roughly an hour, I was shown images on a screen. I gazed at beautiful landscapes and abstract paintings to establish a baseline, but most of the images were of foods or drinks: glasses of frothy beer nestled in snow; a bottle of red wine next to a bowl of grapes; celery, apples, doughnuts, burgers. Occasionally, a prompt asked me to rate my desire to drink.

大约一个小时里,屏幕上不断闪现各种图像。我凝视着美丽的风景和抽象画作——这些是用来建立基准线的,但大部分画面都是食物或饮品:雪堆中冒着泡沫的啤酒杯,盛着葡萄的碗旁那瓶红酒,还有芹菜、苹果、甜甜圈、汉堡。偶尔,屏幕上会跳出提示,要求我评估此刻想喝酒的渴望程度。

Later, on a computer, Schacht pulled up scans that showed what addiction looks like in the brain. Harmful alcohol use is strongly correlated with bright-red splotches in two specific areas, he said. The first, a circle where the hemispheres meet, is the ventral striatum. “That’s where all these dopamine-producing neurons release their dopamine in response to alcohol and other drugs,” Schacht said. Notably, the area is also rich in receptors for naturally occurring GLP-1. The other area, an elongated oval near the front of the brain, is in the medial prefrontal cortex, which is involved in higher-level evaluations of rewards. “It says, ‘Hey, this is something worth chasing!’ ” Schacht told me. Together, the splotches represent a kind of neural signature for craving. “It’s what we hope GLP-1 medications can dampen,” he said.

后来,沙赫特在电脑上调出扫描图像,展示了成瘾在大脑中的样貌。他说,有害的酒精使用与两个特定区域的鲜红色斑块密切相关。第一个区域位于大脑半球交汇处,呈圆形,是腹侧纹状体。“那里聚集着大量多巴胺能神经元,会在酒精和其他药物刺激下释放多巴胺,”沙赫特解释道。值得注意的是,这个区域也富含天然GLP-1的受体。另一个区域靠近大脑前部,呈细长椭圆形,位于内侧前额叶皮层,负责对奖赏进行更高层次的评估。“它会发出信号:'嘿,这东西值得追求!'”沙赫特告诉我。这些斑块共同构成了渴求的神经特征标记。“这正是我们希望GLP-1药物能够抑制的,”他说。

I was struck by how different the images of my brain looked: largely black and white, with only a faint dusting of color. “Good news,” Schacht said. “You don’t have alcohol-use disorder.” On some level, I’d already understood addiction to be a treatable disease, not a personal failing. Still, these scans helped me appreciate how deeply addiction is rooted in neurobiology. A mere photograph of alcohol—to say nothing of a sip—was enough to send a person’s reward centers into a frenzy. Our decisions still matter; the red circles are known to grow brighter when they’re conditioned by repeated use of a drug. But it was counterproductive, even biologically incoherent, to shame a person for having overwhelming cravings. If GLP-1 drugs prove successful, they might reset not only people’s addictions but also society’s perceptions.

我震惊于自己大脑影像的差异:基本是黑白的,只有零星几抹色彩。“好消息,”沙赫特说,“你没有酒精使用障碍。”某种程度上,我早已明白成瘾是一种可治疗的疾病,而非个人缺陷。但这些扫描图像仍让我深刻体会到,成瘾如何深植于神经生物学之中——仅仅是酒精的照片(更不用说浅尝一口),就足以让人的奖赏中枢陷入疯狂。我们的选择依然重要;那些红色圆圈在反复用药的强化下会愈发鲜亮。但因此去羞辱那些被强烈渴望吞噬的人,不仅徒劳无益,甚至在生物学层面都说不通。如果GLP-1类药物最终被证实有效,它们或许不仅能重置人们的成瘾机制,也能重塑社会对成瘾的认知。

Schacht is still analyzing data from the fifty people in his trial, but he shared some preliminary findings. Before the study, participants consumed nearly seven drinks a day; two months later, people on semaglutide drank half as much. The number of days on which they drank heavily—four or more drinks for women, five or more for men—fell from roughly two-thirds to a quarter. “My emotional response to alcohol was totally cut off,” Susan told me. Before she joined the study, if she found herself in the wine aisle of a grocery store, she’d buy five bottles. Afterward, she told me, “my brain recognized it—like, Oh, that’s what you used to want—but my body had no desire for it.” She said that when she repeated the cue-reactivity test at the end of the trial, the glass of wine “had absolutely no pull.” Strikingly, the drug didn’t make people any more likely to abstain from alcohol. It only led them to consume fewer drinks. “This, to me, is the most meaningful result,” Schacht said. “Most patients don’t want to be completely abstinent. They want to drink like a ‘normal person.’ ”

沙赫特仍在分析试验中五十名参与者的数据,但他分享了一些初步发现。研究开始前,参与者日均饮酒量接近七杯;服用司美格鲁肽两个月后,饮酒量减半。他们酗酒(女性单日四杯以上,男性五杯以上)的天数比例从约三分之二降至四分之一。“酒精再也无法牵动我的情绪了,”苏珊告诉我。加入研究前,若在超市酒类区驻足,她会买下五瓶葡萄酒。用药后她坦言:“我的大脑能识别那种渴望——哦,这就是你从前想要的——但身体已毫无欲望。”她说在试验末期重复线索反应测试时,那杯葡萄酒“彻底失去了吸引力”。值得注意的是,这种药物并未提高人们的戒酒率,只是减少了饮酒量。“这在我看来是最有意义的结果,”沙赫特说,“多数患者并不想完全戒除,他们只希望像'正常人'那样饮酒。”

Aristotle argued that the path to a life well lived runs through moderation. Courage lies somewhere between cowardice and recklessness, generosity between stinginess and extravagance. “It is best to rise from life as from a banquet, neither thirsty nor drunken,” he is often quoted as saying. GLP-1s have earned a reputation as “moderation molecules.” For many people, these drugs might restore a sense of control, offering a path away from excess. “GLP-1s are the most exciting drugs for alcohol-use disorder I’ve seen in my career,” Schacht said. “This could be our Prozac moment.”

亚里士多德认为,通往美好生活的道路在于恪守中庸之道。勇气介于怯懦与鲁莽之间,慷慨介于吝啬与挥霍之间。他常被引用的那句名言是:“最好从生活中起身,如同从宴席中离席,既不觉口渴,也未至酩酊。”GLP-1类药物因此赢得了“节制分子”的美誉。对许多人而言,这类药物或许能帮助他们重获掌控感,提供一条远离放纵的路径。“GLP-1是我职业生涯中见过治疗酒精使用障碍最令人振奋的药物,”沙赫特表示,“这可能会成为我们的'百忧解时刻'。”

This doesn’t mean that GLP-1s will be a panacea. When Prozac débuted, in the late eighties, it represented a fundamental shift in the treatment of depression. Millions of people who lacked effective options for a distressing condition suddenly had one; by 2008, antidepressants were the third most common prescription drugs in the U.S., behind cholesterol medications and painkillers. Yet Prozac’s legacy is complicated. Its reputation as a miracle drug outpaced evidence of its medical benefit, and it propagated a narrative of depression as a chemical imbalance that later proved incomplete, if not untrue. Many people took it and said that they no longer felt depressed, but many also said that they no longer felt like themselves.

这并不意味着GLP-1类药物会成为万能灵药。上世纪八十年代末,当百忧解(Prozac)首次问世时,它代表着抑郁症治疗方式的根本性转变。数百万饱受痛苦却缺乏有效治疗方案的患者突然看到了希望;到2008年,抗抑郁药已成为美国第三大常用处方药,仅次于降胆固醇药物和止痛药。然而百忧解的遗产是复杂的。它作为“奇迹药物”的声誉超越了其医学效益的实际证据,并催生了将抑郁症简单归因于“化学失衡”的叙事——这种理论后来被证明即便不算错误,至少也是不完整的。许多人服用后表示不再感到抑郁,但也有许多人说自己仿佛失去了原本的自我。

Recently, I spoke with a fortysomething woman I’ll call Jessica, who struggled with untreated A.D.H.D. for decades. She told me that her “treatment” was food and alcohol. For much of her life, she binged on both; when she entered menopause, she started to put on weight. She saw an advertisement for a GLP-1 medication from a telehealth company and decided to try it out. A few days later, she received a box of syringes in the mail.

最近,我和一位四十多岁的女性聊了聊,我称她为杰西卡,她几十年来一直与未接受治疗的注意力缺陷多动障碍作斗争。她告诉我,她的“治疗”就是食物和酒精。在她人生的大部分时间里,她对这两者都暴饮暴食;进入更年期后,她开始发胖。她看到一家远程医疗公司发布的GLP-1药物广告,决定试一试。几天后,她收到了一盒注射器。

Jessica lost twenty pounds in the four months after she started injecting herself, but her drinking was largely unaffected. Meanwhile, she grew more anxious. Her husband noticed her mood worsening; she lost interest in activities she’d previously enjoyed. An avid gardener, she had planned to refresh her yard with six Japanese maple trees, but now she couldn’t bring herself to plant them. “That’s when I was, like, Whoa, this isn’t my normal,” she said. She covered the windows looking into her garden so that she wouldn’t have to see her withering plants. For her, the GLP-1 medication didn’t moderate so much as agitate and numb. Eventually, she decided that the psychological side effects weren’t worth the weight loss. She stopped taking the medication and regained the weight, but her mood improved. “It was pretty immediate—the return to feeling like myself,” she said.

杰西卡开始给自己注射药物后的四个月里瘦了二十磅,但她的饮酒习惯基本没受影响。与此同时,她变得愈发焦虑。丈夫注意到她的情绪越来越糟;她对以前喜欢的活动失去了兴趣。作为一个园艺爱好者,她原本计划用六棵日本枫树装点庭院,如今却提不起劲去栽种。“那时我就想,哇,这不像平时的我。”她说。她用窗帘遮住朝向花园的窗户,以免看见日渐枯萎的植物。对她而言,GLP-1药物与其说是调节,不如说是刺激与麻木。最终她认定,为减重承受心理副作用并不值得。停药后体重虽然反弹,但情绪明显好转。“那种回归自我的感觉来得很快。”她说。

Jessica seemed to be describing anhedonia, a struggle to experience pleasure. Last year, the New York Times interviewed two dozen people whose relationships were affected by GLP-1 drugs, including a woman who lost interest in sex. In “Magic Pill,” the journalist Johann Hari attributes a muted mood to Ozempic. “I didn’t feel as excited for the day ahead,” he writes. “I was often emotionally dulled.” On Reddit, users discuss numerous psychological changes. “I wasn’t enjoying my family at all, or myself, or my life,” one person wrote. “I don’t want to be a zombie.” Jens Juul Holst, a Danish scientist credited with helping discover GLP-1, worried, in 2023, that GLP-1 medications would make life “so miserably boring that you can’t stand it any longer and you have to go back to your old life.”

杰西卡描述的似乎是快感缺乏症(anhedonia),即难以体验到愉悦感。去年,《纽约时报》采访了二十多位因GLP-1类药物而影响人际关系的人士,其中一位女性甚至对性失去了兴趣。在《神奇药丸》一书中,记者约翰·哈里将情绪麻木归因于司美格鲁肽(Ozempic)。他写道:“我不再对即将到来的一天感到兴奋,情绪常常处于迟钝状态。”在Reddit论坛上,用户们讨论了诸多心理变化。有人写道:“我完全无法从家庭、自我或生活中获得乐趣,我不想变成行尸走肉。”被誉为GLP-1发现者之一的丹麦科学家延斯·尤尔·霍尔斯曾在2023年担忧,GLP-1药物可能会让生活“变得如此沉闷乏味,令人难以忍受,最终迫使患者回归从前的生活方式”。

These anecdotes raise the possibility that the so-called moderation molecule has an alter ego—as a desire dampener that can go too far. Maybe some people who take GLP-1s lose interest in drugs and alcohol because they lose interest in everything. In 2023, after scores of reports of suicidal thoughts and self-harm among people taking GLP-1s, the European Medicines Agency initiated a safety review. The agency ultimately concluded that the available evidence did not establish a causal link between the medications and suicidal thoughts or behaviors. (The U.S. Food and Drug Administration noted in 2024 that it could not “definitively rule out that a small risk may exist,” but requested last month that suicide warnings be removed from GLP-1 drugs.) The data remain frustratingly ambiguous. Observational studies, which tend to be less precise than randomized controlled trials, have found that GLP-1s might harm or help a person’s mental health. The Nature network of journals recently published an article suggesting that GLP-1s reduce the risk of suicidal thoughts by more than half—and another article saying that they more than double the risk of suicidal behavior. Nearly all the experts I spoke with said that we needed more research.

这些轶事让人不禁怀疑,所谓的“节制分子”或许还有另一副面孔——它可能是一种欲望抑制剂,但有时会矫枉过正。或许某些服用GLP-1类药物的人之所以对毒品和酒精失去兴趣,是因为他们对所有事物都失去了兴趣。2023年,在收到大量关于GLP-1类药物使用者产生自杀念头和自残行为的报告后,欧洲药品管理局启动了安全性审查。该机构最终得出结论,现有证据无法证实这些药物与自杀念头或行为之间存在因果关系(美国食品药品监督管理局在2024年指出,虽然“不能完全排除存在微小风险的可能性”,但已于上月要求取消GLP-1类药物的自杀风险警示)。相关数据至今仍令人困惑地模棱两可。观察性研究(通常不如随机对照试验精确)发现,GLP-1类药物既可能损害也可能改善人的心理健康。《自然》期刊网络最近发表的一篇文章指出,GLP-1类药物能将自杀念头风险降低一半以上——而另一篇文章却称其会使自杀行为风险增加一倍以上。几乎所有与我交谈过的专家都表示,我们需要更多研究。

When we take a medicine in the hope that it will curb a particular desire, we’re meddling with a complex system, Sarah Kawasaki, the chief of addiction services at Penn State Health, told me. Kawasaki portrayed addiction as a legitimate evolutionary adaptation—the pursuit of pleasure—gone haywire. Enjoyment of food encouraged our ancestors to nourish themselves; enjoyment of sex encouraged them to procreate. “When it’s not in its extreme form, pleasure-seeking is what led to the success of this species,” Kawasaki said. Tampering with it can have side effects. “You need joy in life,” she told me. “What happens when you blanket a society in GLP-1s? Do we all turn into boring, listless people?” A small minority of the population seems to report anhedonia after taking GLP-1s, and other mental-health consequences—irritability, insomnia, apathy, brain fog—are probably only slightly more common. But the rapid spread of these medications is, essentially, a vast social experiment. Drugs are generally approved based on controlled studies of several hundred individuals. Now tens of millions of people are taking GLP-1s, and we’re discovering, in real time, the full range of their effects.

宾夕法尼亚州立大学健康中心成瘾服务部主任莎拉·川崎(Sarah Kawasaki)告诉我,当我们服用某种药物以期抑制特定欲望时,其实是在干预一个复杂的系统。川崎将成瘾描述为一种合理的进化适应机制——对愉悦感的追求——失控后的状态。享受食物促使我们的祖先摄取营养;享受性爱促使他们繁衍后代。“当这种机制未走向极端时,追求愉悦正是人类物种成功繁衍的关键,”川崎说。干预这种机制可能产生副作用。“人活着需要快乐,”她告诉我,“当整个社会都笼罩在GLP-1药物的影响下时会发生什么?我们会全都变成乏味麻木的人吗?”目前仅有极少数人群报告在服用GLP-1药物后出现快感缺失症状,其他心理健康影响——易怒、失眠、冷漠、脑雾——可能也只是略微常见些。但这些药物的迅速普及本质上是一场大规模社会实验。药物审批通常基于对数百人开展的对照研究,而现在数千万人正在服用GLP-1类药物,我们正在实时探索其全部影响范围。

It’s surprisingly difficult to say what turns a given behavior into an addiction. The answer probably has to do with pleasure, and with strong cravings, but a person can of course experience both without being addicted to anything. In “The House at Pooh Corner,” Winnie-the-Pooh remarks that “although Eating Honey was a very good thing to do, there was a moment just before you began to eat it which was better than when you were.” Meanwhile, Tantalus, the Greek mythological figure who lent his name to the word “tantalize,” was condemned to hunger and thirst in a pool beneath a fruit tree; the water ebbed whenever he tried to drink, and the fruit receded whenever he tried to eat. We don’t usually think of Pooh or Tantalus as having addictions. Yet a person in the throes of one might identify with either character, depending on whether the drug is within reach.

要界定某种行为何时会演变成成瘾,出人意料地困难。答案或许与快感和强烈的渴求有关,但一个人当然也可能体验这两者却未对任何事物上瘾。在《小熊维尼的小屋》中,维尼熊曾说过:“虽然吃蜂蜜是件很棒的事,但在开始吃之前的那一刻,比真正吃的时候更美妙。”与此同时,希腊神话人物坦塔洛斯(他的名字衍生出“诱惑”一词)被罚站在果树下的水池中忍受饥渴:每当他试图饮水,水位便退去;每当他试图摘果,树枝便升高。我们通常不会认为维尼熊或坦塔洛斯有“成瘾”问题。然而,沉溺于某种瘾症的人或许能在两者身上找到共鸣——区别仅在于成瘾物是否触手可及。

Opponent-process theory, refined in the seventies by the psychologists Richard Solomon and John Corbit, holds that the body balances out the high of a drug with the opposing force of a comedown or a withdrawal. In their view, addiction tends to dull the high but not the low, causing a disruption in a person’s “hedonic homeostasis.” In other words, people start taking a drug because it makes them feel good but go on taking it to avoid feeling bad; the dread of deprivation eventually dominates.

“对立过程理论”(opponent-process theory)由心理学家理查德·所罗门(Richard Solomon)和约翰·科比特(John Corbit)在二十世纪七十年代完善。该理论认为,人体会通过戒断反应或情绪低谷的反作用力来抵消药物带来的亢奋感。在他们看来,成瘾往往会钝化快感,却无法缓解低谷,从而破坏人的“享乐稳态”。换言之,人们最初吸毒是为了获得愉悦,但持续吸毒却是为了避免痛苦——对匮乏的恐惧终将占据上风。

In the eighties, Kent Berridge, a neuroscientist at the University of Michigan, tried to study these dynamics on a biochemical level. The neurotransmitter dopamine was understood as a driver of pleasure and therefore a mediator of addiction; in one experiment, Berridge and his colleagues gave sugar water to dopamine-deprived rats. If pleasure depended wholly on dopamine, then the rats presumably wouldn’t have enjoyed the sweetness, but curiously they appeared to experience just as much pleasure as normal rats did. What changed was the rats’ willingness to work for the sugar water. A dearth of dopamine seemed to destroy their motivation.

上世纪八十年代,密歇根大学的神经科学家肯特·贝里奇(Kent Berridge)试图从生化层面研究这种动态机制。当时学界认为,神经递质多巴胺是愉悦感的驱动因素,因而也是成瘾行为的中介物;在一项实验中,贝里奇与同事给多巴胺水平被抑制的老鼠喂食糖水。如果愉悦感完全依赖多巴胺,这些老鼠理应尝不出甜味带来的快感,但奇怪的是,它们表现出的愉悦反应与正常老鼠并无二致。真正改变的是老鼠为获取糖水付出的意愿——多巴胺的匮乏似乎摧毁了它们的行动动机。

In another study, Berridge linked the effects of dopamine with pleasant stimuli (sugar water and cocaine) and an unpleasant stimulus (a shock from an electrified rod). Each stimulus was paired with laser stimulation of a brain region called the amygdala, mimicking a dopamine hit. Oddly, the rats became just as entranced by the rod as they were by the sugar water or the cocaine. They seemed to want something that they clearly didn’t like. “I thought, My God, it’s the perfect prototype for addiction,” Berridge told me. “The wanting gets totally divorced from the liking.” People with addictions may seek a drug even when it no longer makes them feel good. For an addiction treatment to succeed, then, it might need to do more than render a drug unpleasant.

在另一项研究中,贝里奇将多巴胺的作用与愉悦刺激(糖水和可卡因)及厌恶刺激(电击棒)联系起来。每种刺激都配合激光刺激大脑杏仁核区域,模拟多巴胺释放。奇怪的是,老鼠对电击棒的痴迷程度竟与对糖水或可卡因无异。它们似乎在追求某种显然并不喜欢的东西。“我当时想,天啊,这简直是成瘾的完美原型,”贝里奇告诉我,“渴求与喜好完全分离了。”成瘾者即使在药物不再带来快感时仍会继续追寻。因此,要成功治疗成瘾,或许需要做的不仅是让药物变得令人厌恶。

Many researchers believe that Ozempic and its chemical cousins act through the brain’s mesolimbic pathway, which is sometimes called the reward system. Alcohol, nicotine, cocaine, and opioids increase dopamine release in the pathway; so do gambling and social media. “Sex, drugs, sports cars—those things just light up the mesolimbic system,” Berridge said. “You want world peace, a good career, a nice family? Those are great wants, but they’re not mesolimbic dopamine wants.” This may explain why we don’t become addicted to our ideals or our families, and why these commitments aren’t usually affected by GLP-1 drugs. The specific ways that GLP-1s affect the mesolimbic system may also help explain how, at least in some people, they induce moderation. In animal studies, GLP-1s have been shown to limit spikes of dopamine, but not baseline levels, in the brain. When mice on the medications are given cocaine, they experience smaller surges of dopamine than normal mice, but otherwise they maintain adequate amounts of the neurotransmitter. The drugs may calm the water without draining the pool.

许多研究者认为,司美格鲁肽及其化学同类药物是通过大脑的中脑边缘通路起作用的,这条通路有时被称为奖赏系统。酒精、尼古丁、可卡因和阿片类药物会增加该通路中的多巴胺释放;赌博和社交媒体也是如此。“性、毒品、跑车——这些东西会点亮中脑边缘系统,”贝里奇说。“你想要世界和平、事业有成、家庭美满?这些都是美好的愿望,但它们不是中脑边缘多巴胺的渴望。”这或许可以解释为什么我们不会对理想或家庭上瘾,以及为什么这些承诺通常不受GLP-1药物的影响。GLP-1药物影响中脑边缘系统的具体方式,也可能有助于解释它们如何在至少部分人群中诱导适度行为。动物研究表明,GLP-1药物能限制大脑中多巴胺的峰值水平,但不影响基础水平。当服用此类药物的小鼠被给予可卡因时,它们经历的多巴胺激增幅度小于正常小鼠,但除此之外仍能维持足够的神经递质水平。这些药物或许能平息波澜,却不会抽干池水。

If this explanation is correct, then it’s just as Mary said: these drugs may have their most surprising effects not in the gut but in our brains. Indeed, when researchers knock out GLP-1 receptors in rodent brains, the drugs no longer combat obesity. (They still work as an anti-diabetes medicine.) Yet these clues about how GLP-1s work have given rise to another mystery. As scientists have tinkered with GLP-1s, transforming a short-lived peptide into long-lasting injections, the molecules have grown large enough that they shouldn’t be able to cross the blood-brain barrier. So how do they impact the brain? Scientists have theories. Maybe the drugs transmit signals through the vagus nerve, which connects the brain to other organs; maybe they boost production in the brain’s own small GLP-1 factory; maybe they seep in through small windows that are less protected, such as the teardrop-shaped area postrema, sometimes called the vomit center. (The latter might have something to do with a side effect of GLP-1s: nausea.) “The truth is, no one really knows,” Lorenzo Leggio, a physician scientist and a clinical director at the National Institutes of Health, told me.

如果这一解释成立,那么正如玛丽所言:这些药物最令人惊讶的效果可能并非作用于肠道,而是作用于我们的大脑。事实上,当研究人员敲除啮齿动物大脑中的GLP-1受体后,这类药物便不再具有抗肥胖效果(但仍可作为抗糖尿病药物使用)。然而,这些关于GLP-1作用机制的线索却引出了另一个谜团:随着科学家对GLP-1分子进行改造——将短效肽转化为长效注射剂——分子结构已大到理论上无法穿过血脑屏障。那么它们究竟如何影响大脑?科学家们提出了几种假说:或许药物通过连接大脑与其他器官的迷走神经传递信号;或许它们促进了大脑自身小型GLP-1工厂的产量;又或许是通过血脑屏障防护较弱的“窗口”渗入,比如泪滴状的最后区(area postrema)——这个有时被称为呕吐中枢的区域(后者或许与GLP-1类药物引起的恶心副作用有关)。“真相是,其实没人真正清楚,”美国国立卫生研究院的医师科学家兼临床主任洛伦佐·莱吉奥(Lorenzo Leggio)告诉我。

Berridge’s discovery—that it’s possible to want something you no longer like—has become widely influential in addiction medicine. But Patricia (Sue) Grigson, the chair of the department of neuroscience and experimental therapeutics at Penn State, believes that there’s a third dimension. Addiction, Grigson told me, is more than psychological; she sees it as a physiological drive similar to that for food or water. There’s wanting and liking—and then there’s needing. A few months ago, Grigson showed me around a basement at Penn State’s medical school which smelled of fur, feed, and sawdust. On one side stood a dozen or so cages occupied by snow-white rats. On the opposite wall was an empty chamber next to a small black platform and a tangle of tubing. “That’s where the fentanyl goes,” Grigson said. The tubing could be connected, via a catheter, directly to a rat’s bloodstream. Using this contraption, Grigson has performed sophisticated experiments on GLP-1s and addiction. By repeatedly licking an empty spout, rats could “earn” an infusion of fentanyl. (“We’ve never had an animal overdose in the chamber,” Grigson said, solemnly.)

贝里奇的发现——你可能想要自己不再喜欢的东西——在成瘾医学领域产生了广泛影响。但宾夕法尼亚州立大学神经科学与实验治疗学系主任帕特里夏·苏·格里格森认为,成瘾还有第三个维度。格里格森告诉我,成瘾不仅是心理问题;她将其视为类似对食物或水的生理性驱动力。除了“想要”和“喜欢”,还有“需要”。 几个月前,格里格森带我参观了宾州医学院的一个地下室,那里弥漫着皮毛、饲料和锯末的气味。一侧排列着十几个笼子,里面养着雪白的老鼠。对面墙上有个空置的隔间,旁边是个黑色小平台和一堆缠绕的导管。“那是放置芬太尼的地方,”格里格森说。这些导管可以通过留置针直接连接到老鼠的血液中。利用这套装置,格里格森对GLP-1类药物与成瘾关系进行了精密实验。老鼠通过反复舔舐空管嘴来“赚取”芬太尼注射。格里格森严肃地告诉我:“从没有动物在实验舱内过量致死。”
Plumber and woman looking at basement leak with fish in it.
“I can fix it. But the fish will die.”
“我能修好。但鱼会死。”
Cartoon by Edward Steed
Copy link to cartoon
Shop

In one experiment, rats addicted to fentanyl were treated with either liraglutide, an older GLP-1 medication, or salt water. At first, the fentanyl syringe was kept empty—no matter what the rats did, they weren’t getting any more of the drug. Rats that had been injected with salt water engaged in drug-seeking behavior: they lapped at the spout more than a hundred times. “It didn’t do them a lick of good!” Grigson said. Rats on liraglutide, however, stopped after a few dozen attempts. They barely seemed to want the drug.

在一项实验中,研究人员给对芬太尼上瘾的大鼠分别注射了老款GLP-1药物利拉鲁肽和生理盐水。起初,芬太尼注射器保持空置状态——无论大鼠做什么,它们都无法获得更多药物。注射生理盐水的大鼠表现出明显的觅药行为:它们舔舐注射口超过百次。“这对它们毫无益处!”格里格森说。然而,接受利拉鲁肽治疗的大鼠在尝试几十次后便停止了。它们似乎根本不再渴求药物。

When Grigson’s team examined the brains of the rats on liraglutide, fentanyl-seeking wasn’t causing its usual spikes of activity in the mesolimbic pathway; GLP-1s appeared to lower the perceived rewards of the drug. “Now, here’s the really interesting thing,” Grigson said. The medication also dramatically suppressed activity in the locus coeruleus, an area involved in withdrawal and aversion. GLP-1s seemed to be having a moderating effect not only because they made fentanyl less pleasurable—but also because they made abstinence less painful.

当格里格森的团队检查服用利拉鲁肽的大鼠大脑时,发现觅食芬太尼的行为并未像往常那样引起中脑边缘通路的活动激增;GLP-1类药物似乎降低了毒品带来的感知奖赏。“现在,真正有趣的现象出现了,”格里格森说。这种药物还显著抑制了蓝斑核的活动——这个脑区与戒断反应和厌恶情绪密切相关。GLP-1类药物似乎能产生双重调节作用:既让芬太尼带来的快感减弱,又使戒断过程的痛苦减轻。

Kawasaki, at Penn State Health, considered Grigson’s rat studies so astonishing that they began working together. “Humans are not rats—for the most part, anyway,” Kawasaki told me. “It was clear that we needed to test these medications in humans.” Decision-making is far more complex in humans than in other animals. The regions of the human brain that are affected by GLP-1s are embedded in a large cerebral cortex, which is involved in higher-order functions such as learning, memory, and consciousness. “The cortex is the cause and the cure,” Kawasaki said. “People have agency in a way that rats don’t. Ultimately, we can still make horrible decisions for ourselves.”

宾夕法尼亚州立健康中心的川崎认为格里格森的鼠类实验如此惊人,于是两人开始合作。“人类毕竟不是老鼠——至少大多数情况下不是,”川崎告诉我,“显然我们需要在人类身上测试这些药物。”人类的决策机制远比动物复杂。受GLP-1类药物影响的人类大脑区域深嵌于巨大的大脑皮层中,而皮层涉及学习、记忆、意识等高级功能。“皮层既是问题的根源,也是解药所在,”川崎说,“人类拥有老鼠不具备的主观能动性。归根结底,我们依然可能为自己做出糟糕的决定。”

Kawasaki collaborated on a human trial for opioid addiction led by Grigson and Scott Bunce, a clinical psychologist at Penn State. Because liraglutide was being tested on a vulnerable population, they recruited twenty people at a residential treatment center where they could closely monitor participants. (“Someone might say, ‘These people are already thin,’ ” Kawasaki told me. “ ‘Now you’re going to give them a weight-loss drug?’ ”) Ten people received a placebo, and ten received liraglutide. The results were promising: people on liraglutide reported forty per cent fewer cravings. The differences were especially pronounced in the evenings, when cravings tend to peak.

川崎与宾夕法尼亚州立大学的临床心理学家格里格森和斯科特·邦斯合作,开展了一项针对阿片类药物成瘾的人体试验。由于利拉鲁肽的测试对象属于脆弱人群,研究团队在一家住宿式治疗中心招募了二十名参与者,以便进行密切监测。(“或许有人会说,'这些人本来就很瘦了',”川崎告诉我,“现在还要给他们用减肥药?”)其中十人接受安慰剂,十人接受利拉鲁肽注射。结果令人鼓舞:使用利拉鲁肽的受试者报告药物渴求感降低了百分之四十。这种差异在夜晚尤为明显——通常这正是渴求感达到峰值的时段。

Kawasaki is now helping lead a trial of hundreds of people with opioid addiction. This time, participants live in the community, not in a treatment center, and they are on multiple medications: semaglutide, as well as either methadone or buprenorphine, two opioid treatments that curb cravings of drugs such as heroin. “People with hypertension walk around on three or four blood-pressure medicines all the time,” Kawasaki said. “If one medication doesn’t work, we add another and then another until the condition is under control. We haven’t had that option with addiction, and it’s been profoundly limiting.”

川崎(Kawasaki)目前正牵头对数百名阿片类药物成瘾者进行一项试验。这一次,参与者生活在社区而非治疗中心,并且同时服用多种药物:司美格鲁肽(semaglutide),以及美沙酮(methadone)或丁丙诺啡(buprenorphine)中的一种——后两者是用于抑制海洛因等毒品渴求的阿片类治疗药物。“高血压患者常年同时服用三四种降压药,”川崎说,“如果一种药不起效,我们就加另一种,再加一种,直到病情得到控制。在成瘾治疗领域,我们从未有过这样的选择,这极大地限制了治疗的可能性。”

In the lobby of her clinic, a squat brick building in Harrisburg, Pennsylvania, Kawasaki introduced me to Adrienne Pierce, a fifty-year-old woman in the trial. Pierce, who wore a bandanna and camouflage leggings, had tattoos of butterflies and flowers on her arms. In a counselling space that resembled a living room, she told me that she’d cycled through foster homes as a kid. She was raped at sixteen and afterward began using marijuana, alcohol, crack, and eventually heroin. She had a son who was taken into state custody shortly after birth, and she spent most of her twenties in prison. Once she was released, she got married and swore off drugs, but, a few months after the birth of another son, she discovered that her wife had an addiction to Percocet. Pierce’s own drug use returned; a familiar cycle repeated, and the authorities took her second son. Afterward, she achieved another period of sobriety. But it was upended after her wife died, of cardiac issues related to past drug use.

在宾夕法尼亚州哈里斯堡一间矮墩墩的砖砌诊所大厅里,川崎向我介绍了阿德里安娜·皮尔斯(Adrienne Pierce)——这位五十岁的女性正是试验参与者。皮尔斯扎着头巾,穿着迷彩色紧身裤,手臂上纹着蝴蝶与花朵图案。在布置得像客厅的咨询室里,她告诉我,童年时她辗转于多个寄养家庭之间。十六岁那年遭遇强奸后,她开始吸食大麻、酗酒、吸食快克可卡因,最终染上海洛因。她曾有个儿子,出生不久就被政府接管监护;二十多岁的光阴,她大半是在监狱里度过的。出狱后她结了婚,发誓远离毒品,但在另一个儿子出生几个月后,她发现妻子对扑热息痛(Percocet)上了瘾。皮尔斯自己再度开始吸毒;熟悉的循环重演,当局带走了她的第二个儿子。之后她又清醒了一段时间。可当妻子因过往吸毒引发的心脏问题去世后,这一切又被颠覆了。

“I was willing to give Ozempic a shot because I’d never been able to stay completely clean,” Pierce told me. During prior attempts to quit, she had compulsively snacked on candy and gained weight, but this time her weight had stayed steady. The last time she started methadone treatment, it took her six months to stop using heroin; on methadone and semaglutide, it took six weeks. Pierce still had access to drugs and needles, but she had “no desire to touch them,” she said. “It was, like, I don’t even want to get high!” I was struck by how much her description echoed what Mary and Susan had told me. In each case, GLP-1s seemed to ease the pull of an addictive substance in the mind. It was as though by quieting the brain’s response to certain rewards—perhaps dimming the red splotches that I’d seen on the MRI scans—the medications transformed an overpowering emotional response into something that could be seen with detachment, from a distance.

“我愿意试试奥泽匹克(Ozempic),因为我从没能彻底戒断过,”皮尔斯告诉我。此前几次尝试戒毒时,她都会强迫性地吃糖果,体重随之增加,但这次她的体重保持稳定。上次她开始美沙酮治疗时,花了六个月才戒掉海洛因;而这次配合司美格鲁肽(semaglutide),只用了六周。皮尔斯说她仍能接触到毒品和针具,但“完全没有碰它们的欲望”,“就好像,我连嗨都不想嗨了!”令我震惊的是,她的描述与玛丽和苏珊告诉我的如出一辙。在每个案例中,GLP-1类药物似乎都缓解了成瘾物质对心智的拉扯。这些药物仿佛通过抑制大脑对某些奖赏的反应——或许就像我在核磁共振扫描中看到的红色斑块变暗那样——将压倒性的情绪反应转化为某种可以超然远观的事物。

Kawasaki was encouraged by Pierce’s experience. Still, she cautioned against prescribing GLP-1s for opioid addiction before larger and longer-term studies validate their use. There’s a danger in thinking that GLP-1s are a cure, she argued—and not only because the drugs have different effects in different people. “They do nothing to address the why of addiction,” she said: trauma, loneliness, pain, stress, poverty. “Those whys are tangible at first, but over time, as using drugs becomes a coping strategy, they disappear. The whys become an invisible part of what makes it hard for people to make it through the day.”

川崎对皮尔斯的经历感到鼓舞。但她同时提醒,在更大规模、更长期的研究验证其有效性之前,不应将GLP-1类药物用于治疗阿片类药物成瘾。她指出,认为GLP-1是万能解药的想法很危险——这不仅因为药物对不同人群效果各异。“它们完全没有触及成瘾的根源,”她说:创伤、孤独、痛苦、压力、贫困。“这些根源起初是具体的,但随着吸毒成为应对机制,它们逐渐隐没。那些'为什么'变成了无形的存在,成为人们难以捱过每一天的隐形组成部分。”

Pierce is now attending a community college. She has a relationship with her younger son; she’s pursuing a degree in psychology and hopes to open a mental-health center for at-risk teen-agers. “Almost all of us addicts have mental-health issues,” she told me. “People do drugs to numb the pain. If we were talked to when we were younger, maybe we wouldn’t have gotten into drugs in the first place.” GLP-1s are at best a partial solution. They’re not a substitute for mental-health care. And yet, for Pierce, they quieted not only cravings but also ruminations and traumatic memories that triggered her drug use. “The reason I couldn’t get clean in the past is because of the thoughts in my head,” she said. “Ozempic took all that away.”

皮尔斯现在就读于一所社区大学。她与小儿子关系融洽;她正在攻读心理学学位,希望为高危青少年开设一家心理健康中心。“我们这些成瘾者几乎都有心理健康问题,”她告诉我,“人们吸毒是为了麻痹痛苦。如果我们年轻时有人开导,也许一开始就不会沾上毒品。”GLP-1类药物充其量只是部分解决方案,它们不能替代心理健康治疗。但对皮尔斯而言,这些药物不仅抑制了毒瘾,还平息了那些触发她吸毒的强迫性思维和创伤记忆。“过去我无法戒除毒瘾,是因为脑子里那些挥之不去的念头,”她说,“而司美格鲁肽把这一切都带走了。”

It’s a truism in medicine that a drug works only if you take it. As many as half of patients on GLP-1 medications discontinue them within a year, whether because of side effects, access, or cost. Efforts to treat addiction with GLP-1s may face a deeper challenge: even when people stay on them, it’s not clear how long cravings will remain at bay. GLP-1s induce weight loss by altering your sense of fullness; eating enough to maintain your body weight starts to feel like eating too much. The drugs don’t require you to ignore hunger, as a diet would. “The magic sauce here is that people lose weight and they’re less hungry while it’s happening,” Randy Seeley, the director of the Michigan Nutrition Obesity Research Center, said. “If I taped your mouth shut, you’d lose weight, but you’d be more hungry.” Still, when people on GLP-1s reach a new weight plateau—usually within months—they often start to feel hungry again. When it comes to weight loss, this is O.K., since you were never supposed to stop eating altogether. But Seeley fears that a person’s appetite for drugs will return, too, which could prompt a recurrence of drug use.

医学界有句老话:药只有吃下去才管用。多达一半的GLP-1类药物使用者在一年内停药,原因可能是副作用、获取渠道或费用问题。用GLP-1药物治疗成瘾可能面临更深层的挑战:即便患者坚持服药,也难以确定对毒品的渴求能被抑制多久。GLP-1药物通过改变饱腹感来减重——摄入足以维持体重的食物量,会开始让人产生“吃撑了”的感觉。与节食不同,这类药物不需要你对抗饥饿感。“它的神奇之处在于,人们在减重过程中确实没那么饿了,”密歇根营养与肥胖研究中心主任兰迪·西利(Randy Seeley)说,“如果我封住你的嘴,你也会瘦,但饥饿感会更强。”不过,当GLP-1使用者达到新的体重平台期(通常发生在数月内)后,饥饿感往往会卷土重来。就减重而言这无妨,毕竟人本来就不该彻底绝食。但西利担心,人对毒品的渴望也会复苏,这可能诱发复吸。

Clinical trials have generally observed patients for weeks or months; addiction is a chronic disease that can last a lifetime. Even some of Grigson’s rats developed a tolerance to GLP-1s: after they’d been on a dose for a few weeks, their drug-seeking returned. “We’re in this phase right now where some people think these drugs cure everything,” Seeley said. “The hypothesis is that they target food, and then they have all these great spillover effects all over the place. My view is that the spillover is temporary. When the weight loss stops, the spillover stops.” If so, the medications could loosen the grip of an addiction temporarily, without inducing any kind of sustained sobriety. The GLP-1 bubble could still pop.

临床试验通常只观察患者数周或数月;而成瘾是一种可能持续终身的慢性疾病。就连格里格森的一些实验鼠也对GLP-1类药物产生了耐受性:在持续用药数周后,它们重新开始寻求药物。“我们正处在这种阶段——有些人认为这些药物能治愈一切,”西利说,“假设是它们作用于食物,然后产生这些奇妙的溢出效应遍及全身。我的观点是溢出效应是暂时的。当减重停止时,溢出效应也会停止。”果真如此,这些药物或许只能暂时缓解成瘾的控制力,而无法带来持久的清醒。GLP-1热潮仍可能破灭。

If trials like Joseph Schacht’s continue to produce promising results, the F.D.A. could formally approve GLP-1s for the treatment of addiction. But the drugs don’t necessarily need the F.D.A.’s blessing to gain new and widespread uses. (Aspirin was used to prevent repeat heart attacks for decades before the F.D.A. approved it for that use; propranolol, which is officially a blood-pressure drug, is often given for anxiety.) Soon, doctors may have to determine for themselves how to prescribe GLP-1s. How can we predict which patients will benefit, and at what cost? Are GLP-1s a bridge to sobriety or something that patients will need to take indefinitely? If researchers can’t address these questions quickly, patients will supply their own answers.

如果像约瑟夫·沙赫特(Joseph Schacht)这样的临床试验能持续带来积极成果,美国食品药品监督管理局(FDA)或将正式批准GLP-1类药物用于治疗成瘾症。但这类药物要获得新的广泛应用,其实未必需要FDA的官方背书(阿司匹林在获FDA批准用于预防心脏病复发前,早已被临床使用数十年;而官方归类为降压药的普萘洛尔,也常被用于缓解焦虑)。很快,医生们或许就得自行判断如何开具GLP-1类药物处方。我们该如何预判哪些患者能从中获益,代价又是什么?这类药物究竟是通往戒断的桥梁,还是患者需要终身服用的依赖品?若研究者不能尽快解答这些问题,患者终将以自身实践给出答案。

Susan, the former I.C.U. nurse, told me that, after she’d finished Schacht’s trial, she’d gone looking for a way to stay on a GLP-1 drug. A friend eventually directed her to a nurse practitioner who ran a beauty spa. The N.P. wouldn’t formally prescribe the medication for alcohol addiction, Susan told me, but agreed to do so under the cover of her “wanting to lose a few pounds.” Susan now keeps the drug at home and injects herself when she feels that she’s at risk of drinking. Last year, after her husband was given a diagnosis of Stage IV cancer, she briefly restarted the medication. “I knew I needed the GLP to get through that,” she told me. A few months ago, they took a long trip to celebrate a milestone wedding anniversary; Susan injected herself the week before they left. “I didn’t want to be caught at a happy hour and not be content with a Diet Coke,” she said. As a physician, I felt uneasy hearing about the ad-hoc use of a powerful medicine. Susan wasn’t following a doctor’s orders; she was essentially self-medicating. And yet I couldn’t dismiss the results. GLP-1s had helped her more than anything else had. When I last spoke with her, she was still sober. ♦

苏珊曾是一名重症监护室护士。她告诉我,在结束沙赫特的试验后,她开始寻找能继续使用GLP-1药物的途径。后来有位朋友向她推荐了一位经营美容水疗中心的执业护士。苏珊说,这位护士不愿以治疗酒瘾为由正式开具处方,但同意以“想减几磅体重”为名开药。如今苏珊将药物存放在家中,每当感到有饮酒风险时就自行注射。去年,她的丈夫被诊断出四期癌症,她曾短暂恢复用药。“我知道需要GLP-1来度过那个时期。”几个月前,为庆祝结婚纪念日的重要里程碑,他们进行了一次长途旅行;苏珊在出发前一周给自己注射了药物。“我不想在欢乐时光场合只能喝健怡可乐还觉得不满足。”作为一名医生,听到这种强效药物的临时性使用让我感到不安。苏珊并非遵循医嘱,这本质上属于自我药疗。然而我无法否认疗效——GLP-1药物对她的帮助胜过其他任何方法。最近一次交谈时,她仍保持着清醒状态。♦

This article has been updated to clarify that Mary is a pseudonym.

本文已更新,以澄清玛丽为化名。

2 free previews left — register to get 30 translations a month